Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Takes Out $4.5M Credit-Equity Note

NEW YORK, April 22 (GenomeWeb News) - Genaissance Pharmaceuticals has refinanced an existing $2.5 million loan by negotiating a $4.5 million credit-and-equity agreement with New York-based Xmark Funds, a private-equity firm, the company said today.

Genaissance will use the loan to retire the remaining debt on the $2.5-million term loan with Comerica Bank, the company said. Genaissance will use the remaining funds for working capital. The new facility bears a 5-percent interest and is due in full on April 21, 2007, or earlier, depending on Genaissance's liquidity.

Under terms of the agreement with Xmark, Genaissance issued the firm warrants for 2 million shares of common stock at $2.25 apiece. Genaissance closed at $1.24 per share at the close of trading yesterday.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.